B.I.T. Breast in Translation 3.0

Razionale

Breast cancer remains the most frequently diagnosed malignancy among women and the leading cause of cancer-related death worldwide. Despite significant advances in personalized treatment strategies, metastatic breast cancer (MBC) is still an incurable disease for the majority of patients. Understanding its biology and site-specific behavior represents one of the greatest challenges in oncology today.
In particular, the phenomenon of organotropism, the preferential colonization of certain organs by metastatic cells, offers a unique opportunity to decode the mechanisms that drive disease progression and to identify novel therapeutic vulnerabilities. Each metastatic site displays distinct biological features, microenvironmental interactions, and clinical implications that demand a tailored approach.
BIT 2026 aims to provide a brain-shaking, translational forum where clinicians and scientists explore the latest insights into metastatic dissemination, site-specific vulnerabilities, tumor heterogeneity, and the pre-metastatic niche. The program has the goal of inspiring the next generation of clinical scientists to think beyond algorithms and guidelines.
In addition to scientific sessions, BIT 2026 will also foster critical reflection on the culture of oncology and research, addressing themes such as ambition, visibility, role models and work–life balance. By blending science with discussions on the professional and human dimensions of our field, BIT 2026 seeks to build a community committed to excellence, integrity, and innovation in metastatic breast cancer research and care.